Thermo Fisher Scientific Announces CE-IVD Mark for Next-Generation TaqPath COVID-19 RNase P 2.0 Assay Kit

CARLSBAD, Calif., Sept. 16, 2021 /PRNewswire/ -- Thermo Fisher Scientific, the world leader in serving science, today announced the launch of the CE-IVD marked TaqPath COVID-19 RNase P 2.0 kit, a newly designed test that provides accurate results by compensating for current and future COVID-19 viral mutations.

The kit has been redesigned to detect active SARS-CoV-2 infections by identifying the presence of any one of eight gene targets from the virus. By surveying across multiple genes, the test can net accurate results even as mutations shift the genes they express. The TaqPath COVID-19 RNase P 2.0 kit uses an RNase P control to ensure sample integrity, quality and extraction.

"SARS-CoV-2 is continuing to mutate, and this assay is the latest in our efforts to make sure our tests are future proofed against those variants," said Manoj Gandhi, senior medical director for genetic testing solutions, Thermo Fisher Scientific. "With this product, we are offering customers the next generation of our COVID-19 diagnostic test that has inbuilt checks and balances in the face of emerging variants."

The TaqPath COVID-19 RNase P 2.0 kit uses a newly designed assay to assess nasopharyngeal and nasal swab samples to detect active COVID-19 cases. The test has a turnaround time of about three hours. The first-generation test, TaqPath COVID-19 CE-IVD RT PCR Kit, has been available with a CE-IVD mark since March 2020.

For more information on the TaqPath 2.0s platform, please visit: https://www.thermofisher.com/covid19evolved

For In Vitro Diagnostic Use

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 80,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com.

Media Contacts

Mauricio Minotta
Director, Public Relations
Phone: [phone]
E-mail: [e-mail]

Ariane Lovell
FINN Partners
Phone: [phone]
E-mail: [e-mail]